These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 36108558)

  • 21. Top advances of the year: Cervical cancer.
    Podwika SE; Duska LR
    Cancer; 2023 Mar; 129(5):657-663. PubMed ID: 36609769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
    Shi Y; Chen J; Shi B; Liu A
    Gynecol Oncol; 2022 Feb; 164(2):379-385. PubMed ID: 34920886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer.
    McNamara B; Chang Y; Mutlu L; Harold J; Santin AD
    Expert Opin Biol Ther; 2023 Mar; 23(3):227-233. PubMed ID: 36800548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytotoxic and targeted systemic therapy in advanced and recurrent cervical cancer: experience from clinical trials.
    Seol HJ; Ulak R; Ki KD; Lee JM
    Tohoku J Exp Med; 2014 Apr; 232(4):269-76. PubMed ID: 24695215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved survival with bevacizumab in advanced cervical cancer.
    Tewari KS; Sill MW; Long HJ; Penson RT; Huang H; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; Monk BJ
    N Engl J Med; 2014 Feb; 370(8):734-43. PubMed ID: 24552320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
    Chuai Y; Rizzuto I; Zhang X; Li Y; Dai G; Otter SJ; Bharathan R; Stewart A; Wang A
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013348. PubMed ID: 33661538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab for the treatment of cervical cancer.
    Bizzarri N; Ghirardi V; Alessandri F; Venturini PL; Valenzano Menada M; Rundle S; Leone Roberti Maggiore U; Ferrero S
    Expert Opin Biol Ther; 2016; 16(3):407-19. PubMed ID: 26796332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer.
    Garcia-Sayre J; Lin YG; Matsuo K; Tsao-Wei DD; Mhawech-Fauceglia P; Louie S; Dong T; Ciccone MA; Brunette-Masi LL; Pham HQ; Yessaian AA; Groshen SG; Facio G; Aldana M; Muderspach LI; Garcia AA; Roman LD
    Gynecol Oncol; 2023 Jun; 173():49-57. PubMed ID: 37079977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tisotumab vedotin for the treatment of cervical carcinoma.
    Song X; Li R; Wang H; Song P; Guo W; Chen ZS
    Drugs Today (Barc); 2022 May; 58(5):213-222. PubMed ID: 35535813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.
    Monk BJ; Enomoto T; Kast WM; McCormack M; Tan DSP; Wu X; González-Martín A
    Cancer Treat Rev; 2022 May; 106():102385. PubMed ID: 35413489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group.
    Tewari KS; Monk BJ
    Semin Oncol; 2009 Apr; 36(2):170-80. PubMed ID: 19332251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SEOM-GEICO Clinical Guidelines on cervical cancer (2023).
    Manso L; Ramchandani-Vaswani A; Romero I; Sánchez-Lorenzo L; Bermejo-Pérez MJ; Estévez-García P; Fariña-Madrid L; García García Y; Gil-Martin M; Quindós M
    Clin Transl Oncol; 2024 Nov; 26(11):2771-2782. PubMed ID: 39215938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.
    Pierre ME; Manneh R; Hernández A; Rodríguez J; Fletcher AV; Ramírez HM; Niño OM; Gómez DA; Sanabria D; Contreras F; Pieschacón JR; Calderón PH
    Rev Colomb Obstet Ginecol; 2024 Jun; 75(1):. PubMed ID: 39013199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacotherapy for cervical cancer: current standard of care and new perspectives.
    Ketch PW; Zaharias RS; Leath CA
    Expert Opin Pharmacother; 2024 Aug; 25(12):1591-1603. PubMed ID: 39164924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data.
    Agostinelli V; Musacchio L; Camarda F; Salutari V; Carbone MV; Ghizzoni V; Nero C; Ricci C; Perri MT; Giudice E; Lardino S; Berardi R; Scambia G; Lorusso D
    Cancer Manag Res; 2023; 15():1063-1072. PubMed ID: 37790898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
    Vergote I; Van Nieuwenhuysen E; O'Cearbhaill RE; Westermann A; Lorusso D; Ghamande S; Collins DC; Banerjee S; Mathews CA; Gennigens C; Cibula D; Tewari KS; Madsen K; Köse F; Jackson AL; Boere IA; Scambia G; Randall LM; Sadozye A; Baurain JF; Gort E; Zikán M; Denys HG; Ottevanger N; Forget F; Mondrup Andreassen C; Eaton L; Chisamore MJ; Viana Nicacio L; Soumaoro I; Monk BJ
    J Clin Oncol; 2023 Dec; 41(36):5536-5549. PubMed ID: 37651655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.
    Kuo DY; Blank SV; Christos PJ; Kim M; Caputo TA; Pothuri B; Hershman D; Goldman N; Ivy PS; Runowicz CD; Muggia F; Goldberg GL; Einstein MH
    Gynecol Oncol; 2010 Mar; 116(3):442-6. PubMed ID: 19931137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey.
    Richardson MT; Attwood K; Smith G; Liang SY; LaVigne Mager K; Tewari KS; Coleman RL; Kapp DS; Chan JK; Monk BJ
    Cancer Control; 2023; 30():10732748231182795. PubMed ID: 37646470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.